Prognosis of differentiated thyroid cancer in relation to serum thyrotropin and thyroglobulin antibody status at time of diagnosis. - Wikidata - wikimedia - TriplyDB

Prognosis of differentiated thyroid cancer in relation to serum thyrotropin and thyroglobulin antibody status at time of diagnosis.

Prognosis of differentiated thyroid cancer in relation to serum thyrotropin and thyroglobulin antibody status at time of diagnosis.

http://www.wikidata.org/entity/Q37460181

about

2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer Long-Term Outcomes Following Therapy in Differentiated Thyroid Carcinoma: NTCTCS Registry Analysis 1987-2012 Association of Preoperative Serum Thyroid-stimulating Hormone Levels with Thyroid Cancer in Patients with Nodular Thyroid Disease.Clinical aggressiveness and long-term outcome in patients with papillary thyroid cancer and circulating anti-thyroglobulin autoantibodies.New insights in risk stratification of differentiated thyroid cancer.Obesity and risk of thyroid cancer: evidence from a meta-analysis of 21 observational studies.Reassessing the NTCTCS Staging Systems for Differentiated Thyroid Cancer, Including Age at Diagnosis.High Thyroglobulin Antibody Levels Increase the Risk of Differentiated Thyroid Carcinoma.A pilot study of serum selenium, vitamin D, and thyrotropin concentrations in patients with thyroid cancer Pediatric papillary thyroid cancer: current management challenges Thyroid functional parameters and correlative autoantibodies as prognostic factors for differentiated thyroid cancers.Multiple Hürthle cell adenomas in a patient with thyroid hormone resistance A novel integrative risk index of papillary thyroid cancer progression combining genomic alterations and clinical factors.Differentiated thyroid cancer-personalized therapies to prevent overtreatment.Prognostic value of preoperative anti-thyroglobulin antibody in differentiated thyroid cancer.Clinicopathological relevance of antithyroglobulin antibodies in low-risk papillary thyroid cancer.Surgical treatment for thyroid carcinoma: retrospective study with 811 patients in a Brazilian tertiary hospital.Serum thyroglobulin (Tg) monitoring of patients with differentiated thyroid cancer using sensitive (second-generation) immunometric assays can be disrupted by false-negative and false-positive serum thyroglobulin autoantibody misclassifications.PD-L1 and PD-1 expression are correlated with distinctive clinicopathological features in papillary thyroid carcinoma.p63 inhibits CD44+/CD24- cell proliferation and chemoresistance in papillary thyroid carcinoma cells.Preoperative serum thyroglobulin predicts initial distant metastasis in patients with differentiated thyroid cancer.Attributable risk fraction of four lifestyle risk factors of thyroid cancer: a meta-analysis.Unfavorable efficacy to 131I ablation in BRAFV600E mutant papillary thyroid carcinoma with positive TgAb.Vascular endothelial growth factor G+405C polymorphism may contribute to the risk of developing papillary thyroid carcinoma.Mouse Model of Poorly Differentiated Thyroid Carcinoma Driven by STRN-ALK Fusion

P2860

Q30367068-61D9005F-806F-4C38-9D13-318A088B1AA0 Q33570297-9769E086-4090-445B-BBD9-3D58FD064D40 Q33767657-F86DC4C1-7369-4F2E-93A9-A55631D39163 Q33842355-F8951D9F-0AED-4F39-BB2E-AFE260894448 Q33915384-FEE5AD1E-E0C1-4FA5-BFD9-7CD247F1309F Q35044063-F6408DCF-0F2C-4306-926D-5AE231E295DA Q36108073-3DFAEB7A-CC3B-47E1-BF2D-7651069EBFFB Q36265557-AAF6A137-9B53-4A40-901C-C3CD73206B55 Q37163510-66E0B94A-4C3D-4A95-9393-10E76440E08C Q37551856-8D324499-CCC4-43A3-8126-98FA0ED47560 Q37580338-FF0C64B9-2789-441A-8028-1D5288F63951 Q37662277-AAFEEDD4-2034-4232-8B79-7C1358F03C86 Q37725502-44BC95CA-C1A8-45FF-AEFB-223B64F5D2A1 Q38224994-F530CE42-5803-468D-B28E-C83CE8BB6386 Q38792434-51625313-F5CE-403A-B815-B7F6625A315D Q39106373-E50ABF14-B89B-4D46-AB28-8508B603C486 Q39294972-17405B62-62F7-4A95-8AC9-2B0BD0426D28 Q41772758-0AD9B3EA-8156-4DD4-9B0B-118D360D305B Q42247393-0D6463C7-E1C0-4FF4-992B-3A7FECA7B90A Q47098497-04A8AD68-4845-4A4D-B90E-B2FB0BB0A995 Q47112112-42034017-858C-4E76-93CE-3960F3E4DE3C Q49606886-5A979C15-3989-4719-9C25-52347FA6E314 Q49704998-FB09D1A9-0F40-42FD-AAC7-ED272843A92A Q51024629-B54D09EE-AEF5-4FE0-947C-8822F5F69870 Q58701147-4B9E9891-2F7D-4BE3-B685-EE9ED0E5801A

P2860

Prognosis of differentiated thyroid cancer in relation to serum thyrotropin and thyroglobulin antibody status at time of diagnosis.

http://www.wikidata.org/entity/Q37460181

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 04 September 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Prognosis of differentiated th ...... y status at time of diagnosis.

@en

Prognosis of differentiated th ...... y status at time of diagnosis.

@nl

type

label

Prognosis of differentiated th ...... y status at time of diagnosis.

@en

Prognosis of differentiated th ...... y status at time of diagnosis.

@nl

prefLabel

Prognosis of differentiated th ...... y status at time of diagnosis.

@en

Prognosis of differentiated th ...... y status at time of diagnosis.

@nl

P1433

Q37460181-513503E4-C56C-422D-8C04-C722277C9A59

P1476

Q37460181-6FA1F727-5769-4E49-B827-076C9784E133

P2093

Q37460181-059DF2A0-4C65-4778-8E88-9A006AD6F18F

Q37460181-1A63B156-2F96-48D2-A51D-DDD42CD606AE

Q37460181-3FA3DF88-77CD-4163-AC19-8BF971C564A3

Q37460181-504C9B62-5710-4F24-AB41-8662A6A92E0E

Q37460181-537E6758-22FE-4F9A-860E-D76DCDDFDCD8

Q37460181-6151CE29-508C-4ACA-BAAE-F02E69900609

Q37460181-6EE6C54D-A3E3-416C-894C-D7D13BBC4930

Q37460181-785BAC33-BDC6-4B32-AB45-52D88EE51E68

Q37460181-A56B03B7-019C-4D92-8D11-525CF30E1989

Q37460181-A81E9CB4-1FC8-4681-90CA-BCA1BCBD451B

P2860

Q37460181-18FEC418-C7FF-4125-8D55-6A29C0FBD7CC

Q37460181-1A570DD6-AD29-4F1E-9759-8EA7020D1872

Q37460181-28DF6DE2-AB73-4658-80B3-28139DC2B78A

Q37460181-2E5813D5-92F2-4BE8-AB9F-D240AA1ACA15

Q37460181-4405247E-EC7F-46A5-BD6B-F75C46F0D142

Q37460181-5725D6E6-A45A-4FA3-8C27-66033A1A36BD

Q37460181-598D118E-BACF-4105-86BC-D78099E75E31

Q37460181-643F1269-AAAC-4B43-9DBC-05B05E0E2F99

Q37460181-64EF544E-77EF-4C69-B4D1-9AF1226189AF

Q37460181-76A8686A-0051-47BA-889E-C6B78304594F

P304

Q37460181-17E98B69-8F83-4764-AF33-8D2504133958

P31

Q37460181-3798933A-9D21-4E9A-AB07-D99AD1AD80A3

P356

Q37460181-C2A4793B-C9BB-4AAD-8DFE-2CECC68209B5

P433

Q37460181-F8037EEE-4D4C-411D-81C4-84312CDA9006

P478

Q37460181-D5AB0701-FE9C-4E76-8359-7DF974C41922

P50

Q37460181-BAB5AF5F-B3E1-4243-83CC-EFA186E08284

P577

Q37460181-942C146B-9A6F-4CED-94CE-93E6BF35ED01

P698

Q37460181-295C9DAC-352D-4254-A2F4-0C3A00900B49

P921

Q37460181-6ED26540-AC92-4635-BD43-8EC7F336D267

Q37460181-7d17a980-adb0-417d-9c35-0d0e53442f5d

P932

Q37460181-A2DB4C43-E6B6-4769-831F-A3B884E65105

P356

P1433

P1476

Prognosis of differentiated th ...... y status at time of diagnosis.

@en

P2093

Bryan R Haugen

http://www.w3.org/2001/XMLSchema#string

David L Steward

http://www.w3.org/2001/XMLSchema#string

David S Cooper

http://www.w3.org/2001/XMLSchema#string

Donald S A McLeod

http://www.w3.org/2001/XMLSchema#string

Douglas S Ross

http://www.w3.org/2001/XMLSchema#string

Harry R Maxon

http://www.w3.org/2001/XMLSchema#string

Henry G Fein

http://www.w3.org/2001/XMLSchema#string

James D Brierley

http://www.w3.org/2001/XMLSchema#string

James Magner

http://www.w3.org/2001/XMLSchema#string

Kenneth B Ain

http://www.w3.org/2001/XMLSchema#string

P2860

Characterization of thyrotropin receptor antibody-induced signaling cascades

Associations of serum thyrotropin concentrations with recurrence and death in differentiated thyroid cancer.

Higher serum thyroid stimulating hormone level in thyroid nodule patients is associated with greater risks of differentiated thyroid cancer and advanced tumor stage.

Thyrotrophin receptor signaling dependence of Braf-induced thyroid tumor initiation in mice.

BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas.

BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer.

Clinical and pathological implications of concurrent autoimmune thyroid disorders and papillary thyroid cancer

Akt1 deficiency delays tumor progression, vascular invasion, and distant metastasis in a murine model of thyroid cancer

The impact of age and gender on papillary thyroid cancer survival.

Higher serum TSH in thyroid cancer patients occurs independent of age and correlates with extrathyroidal extension

P304

35-42

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1089/THY.2013.0062

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

24

http://www.w3.org/2001/XMLSchema#string

P50

Jacqueline Jonklaas

P577

2013-09-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23731273

http://www.w3.org/2001/XMLSchema#string

P921

P932

3887423

http://www.w3.org/2001/XMLSchema#string